University at Buffalo - The State University of New York
Skip to Content

Faculty and Staff Directory

Gene                           Morse

Gene D. Morse PharmD

Department of Pharmacy Practice

SUNY Distinguished Professor

 
Professional Summary:

Gene D. Morse, Pharm.D., FCCP, BCPS, is a tenured, SUNY Distinguished Professor in the School of Pharmacy and Pharmaceutical Sciences and Director of the UB Center for Integrated Global Biomedical Sciences. He is also the Co-Director of the SUNY Global Health Institute. Dr. Morse has been actively involved in drug development research since the introduction of antiretrovirals for HIV in 1986, with more recent emphasis on HCV infection and drug development. He has National Institute of Allergy and Infectious Diseases support for the UB AIDS Clinical Trials Group, Pharmacology Specialty Laboratory and a contract for the HIV Clinical Pharmacology Quality Assurance Program. These programs integrate with the NIH Fogarty International Center AIDS International Training and Research Program, which Dr. Morse directs with the University of Zimbabwe and is home to the Center of Excellence in Clinical Pharmacology.
Dr. Morse also directs the UB HIV Clinical Pharmacology Laboratory, which has gained an international reputation for its work in bioanalysis, pharmacokinetics, and pharmacogenomics. In addition, Dr. Morse is director of the Empire State Patient Safety Assurance Network, a federally certified patient safety organization and a network for health information technology innovation. Dr. Morse is the director of the UB Translational Pharmacology Research Core. He is also associate director for the Clinical Trials Methods and Technologies Pillar for the Clinical and Translational Sciences Institute at the University of Rochester Medical Center.
Dr. Morse is co-founder of the Buffalo Jamaica Innovation Enterprise, a partnership between UB the University of the West Indies and the Jamaica Ministry of Health. This project has established the Jamaica Center for Infectious Diseases Research. Dr. Morse has more than 25 years of NIH, industry and philanthropic research support with extensive experience in grant applications and mentoring. Dr. Morse received the 2012 Volwiler Research Achievement Award from the American Association of Colleges of Pharmacy.

Education and Training:
  • Fellowship, Clinical Pharmacokinetics, The State University of New York at Buffalo (1984)
  • PharmD, The State University of New York at Buffalo (1983)
  • Residency, Hospital Pharmacy, Moses Cone Memorial Hospital (1981)
  • BS, The State University of New York at Buffalo (1980)
  • BS, The State University of New York at Albany (1976)
  • AAS, Nassau Community College (1974)
Employment:
  • Director, UB Center for Integrated Global Health Sciences (2015-present)
  • Co-Director, UB Clinical and Translational Science Award Drug Development Service, University at Buffalo, SUNY (2015-present)
  • Director, Empire State Patient Safety Assurance Network (2015-present)
  • Director, UB HIV Clinical Pharmacology Laboratory, University at Buffalo, SUNY (2015-present)
  • Associate Director, Clinical Trial Methods and Technologies, for the Clinical and Translational Science Institute, University of Rochester Medical Center (2014-present)
  • SUNY Distinguished Professor, University at Buffalo, SUNY (2014-present)
  • Co-Director, SUNY Global Health Institute (GHI), SUNY (2014-present)
  • Research Professor of Medicine, Physiology and Pharmacology, University of Rochester (2008-present)
  • Director, Translational Pharmacology Research Core, New York State Center of Excellence in Bioinformatics and Life Sciences (2006-present)
  • National Faculty Member, ACCP Focused Investigator Training (2006-present)
  • Research Professor of Pediatrics, University at Buffalo (2004-present)
  • Research Professor of Medicine, University at Buffalo (1998-present)
  • Professor of Pharmacy Practice, University at Buffalo (1996-present)
  • Adjunct Professor, Medicine, Pharmacology and Physiology, University of Rochester Medical Center (URMC), School of Medicine and Dentistry (2015–2016)
  • Director, Antiviral Clinical Pharmacology Unit, Erie County Medical Center (1995–2016)
  • Associate Director, New York State Center of Excellence in Bioinformatics and Life Sciences (2009–2015)
  • Co-Director, UNYTE Translational Research Network, University of Rochester (2010–2014)
  • Associate Director, UB Institute for Healthcare Informatics (2010–2011)
  • Associate Dean, Clinical and Translational Research, University at Buffalo (2007–2009)
  • Research Professor of Medicine, University of Rochester (2001–2008)
  • Director, Pharmacotherapy Research Center, University at Buffalo (2000–2008)
  • Director, Clinical and Translational Sciences Research Institute, University at Buffalo (2006–2007)
  • Associate Dean, University at Buffalo (1998–2007)
  • Chair, Department of Pharmacy Practice, University at Buffalo (1996–2007)
  • Director, Clinical Pharmacology Unit, University of Rochester (2001–2006)
  • Research Associate Professor of Medicine, University at Buffalo (1990–1998)
  • Associate Professor of Pharmacy, University at Buffalo (1989–1996)
  • Research Assistant Professor of Medicine, University at Buffalo (1984–1990)
  • Assistant Professor of Pharmacy, University at Buffalo (1983–1989)
  • Clinical Care Pharmacist, Erie County Medical Center (1981–1982)
See all (20 more)
Awards and Honors:
  • Sir Alister McIntyre Distinguished Award for Outstanding Contributions to the Pharmaceutical Sciences (2016)
  • Honorary Professor (2015)
  • 2015 Buffalo Business First Healthcare Champion (2015)
  • ACCP Institute Research Trustee Nominee (2013)
  • Volwiler Research Achievement Award (2012)
  • Award for Outstanding Contributions to International Education (2010)
  • Top Cited Article Award (2007)
  • UB Textbook Author Recognition (2007)
  • International AIDS Society-USA, Core Faculty Member (2007)
  • Director (2005)
  • Top 100 Principal Investigators (2005)
  • Chancellor's Award for Excellence in Scholarship and Creative Activities (2004)
  • Sustained Achievement Award (2002)
  • Director (2002)
  • Infectious Disease Fellowship (1998)
  • Immunology Fellowship (1996)
  • Fellowship Training Certification (1995)
  • Board Certified Pharmacotherapy Specialist (1992)
  • Infectious Disease Fellowship (1991)
  • Fellow (1991)
  • Who’s Who in the East (1989)
  • Who’s Who in the East (1988)
  • Who’s Who of Emerging Leaders in America (1988)
  • Who’s Who of Emerging Leaders in America (1987)
  • Men of Achievement (1987)
  • Who’s Who in the East (1986)
  • A.B. Lemmon Award (1980)
  • Institutional Practice Award (1980)

Grants and Sponsored Research:
  • May 2015–May 2022
    Clinical Pharmacology Quality Assurance and Quality Control
    NIH/National Institute of Allergy and Infectious Disease
    Role: Principal Investigator
    $12,079,663
  • March 2015–February 2022
    Contract Renewal: Clinical Pharmacology Quality Assurance and Quality Control
    NIH/National Institute of Allergy and Infectious Disease
    Role: Principal Investigator
    $12,754,564
  • January 2014–November 2020
    AIDS Clinical Trials Group, Pharmacology Specialty Laboratory, Federal Flow-through: Task Order 1 SSS
    NIH/National Institute of Allergy and Infectious Diseases
    Role: Principal Investigator
    $2,157,575
  • March 2010–November 2020
    University of Rochester HIV/AIDS Clinical Trials Unit
    NIH/National Institute of Allergy and Infectious Diseases
    Role: Principal Investigator
    $654,419
  • January 2016–January 2020
    Clinical Translational Science Award (CTSA)
    National Institutes of Health
    Role: Co-Investigator
    $16,000,000
  • August 2015–March 2019
    Clinical and Translational Science Award: Buffalo Clinical and Translational Research Center
    NCATS
    Role: Co-Investigator
    $13,151,902
  • April 2013–March 2018
    Chronic Exposure to cART Predispose Older HIV infected individuals to CNS injury
    NIH
    Role: Principal Investigator
    $179,271
  • September 2014–December 2015
    Intrahepatic ABT450 Concentration in Preclinical Models
    Abbvie Pharmaceuticals
    Role: Co-Investigator
  • July 2014–June 2015
    UR Center for AIDS Research – Pharmacokinetics and Immunodynamics of Multi-modal nanoparticles for TB
    Center For AIDS Research (CFAR)
    Role: Co-Investigator
    $171,126
  • October 2012–June 2015
    Women, Infants, Children & Youth Healthcare
    HRSA/Erie County Medical Center
    Role: Principal Investigator
    $205,357
  • July 2010–June 2015
    Center for Human Experimental Therapeutics (CHET)
    NIH/National Center for Research Resources/ University of Rochester
    Role: Principal Investigator
    $296,375
  • June 2012–May 2015
    A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected subjects: Boceprevir, Interferon, Ribavirin to Treat HCV/HIV Coinfected Subjects
    Social and Scientific Systems, Inc
    Role: Principal Investigator
    $499,968
  • June 2012–May 2015
    Pharmacokinetics and Drug Interaction Potential of Boceprevir in HIV/HCV-Coinfected Subjects: A Substudy of A5294
    Social and Scientific Systems, Inc
    Role: Principal Investigator
    $250,000
  • May 2008–May 2015
    Contract: Clinical Pharmacology Quality Assurance and Quality Control
    NIH/National Institute of Allergy and Infectious Disease
    Role: Principal Investigator
    $9,414,158
  • April 2014–March 2015
    Patient Safety Organization
    CCS Oncology
    Role: Principal Investigator
    $185,000
  • June 2012–March 2015
    Standard Administrations Protocol: A Pilot Study to Evaluate ePrescribing and Smart Card Technology
    LFA, Inc
    Role: Principal Investigator
    $116,000
  • April 2009–March 2015
    Antiretroviral Pharmacology Training in Resource Poor Countries
    NIH/Fogarty International Center
    Role: Principal Investigator
    $1,485,319
  • January 2014–December 2014
    Integrating the SUNY 4E Program with the SUNY Global Health Institute
    Research Foundation for SUNY
    Role: Contributor
    $10,000
  • March 2013–December 2014
    PK Analysis of Antiretroviral Drug BIT-225 Clinical Trials
    Biotron
    Role: Principal Investigator
    $35,550
  • January 2013–December 2014
    Multimodal Nanoparticle Formulations for Targeted Drug Delivery and Immunotherapy in Tuberculosis
    NIH/ Brigham and Women’s Hospital
    Role: Principal Investigator
    $250,000
  • January 2001–December 2014
    HIV Treatment Education (Ryan White)
    HRSA/Erie County Medical Center
    Role: Principal Investigator
    $765,450
  • January 2014–November 2014
    AIDS Clinical Trials Group, Pharmacology Specialty Laboratory, Federal Flow-through: ACTG Precautionary and Prohibited Medications Database
    NIH/National Institute of Allergy and Infectious Diseases
    Role: Principal Investigator
    $190,000
  • March 2001–June 2014
    New York State Adherence
    NYS DOH/Erie County Medical Center
    Role: Principal Investigator
    $490,000
  • Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Patients with HIV-1 Co-infection Receiving Concurrent Antiretroviral Therapy (A5329)
    NIH/National Institute of Allergy and Infectious Diseases
    Role: Principal Investigator
    $124,961
  • Pharmacokinetic Studies of Raltegravir and Darunavir/ritonavir Before and During Combined Administration with ABT-450/r, ABT-267, ABT-333 and Ribavirin in HIV-1/HCV Co-Infected Patients (A5334s): A Substudy of A5329
    NIH/National Institute of Allergy and Infectious Diseases
    Role: Principal Investigator
    $57,125
  • Co-infected Adults Treated with HCV Direct Acting Antivirals Plus Ribavirin (A5335s): A Sub-Study of A5329
    NIH/National Institute of Allergy and Infectious Diseases
    Role: Principal Investigator
    $17,629
See all (16 more)

Journal Articles:
See all (125 more)
Books and Book Chapters:
  • Sawyer JR; Acosta EP; Morse ED. Raltegravir. HIV Clinical Manual. 2008.
  • Sawyer JR; Acosta EP; Morse ED. Raltegravir. HIV Clinical Manual. 2008.
  • Morse ED. 2nd Edition: Development and Evaluation of Drugs: From Laboratory through Licensure to Market. 2nd Edition: Development and Evaluation of Drugs: From Laboratory through Licensure to Market. 2001.
  • Morse ED. 1st Edition: Development and Evaluation of Drugs: From Laboratory through Licensure to Market. 1st Edition: Development and Evaluation of Drugs: From Laboratory through Licensure to Market. 1993.
Abstracts:
  • Mudzviti T; Maponga C; Khoza S; Tagwireyi D; Ma Q; Morse ED. Adverse Drug Reactions During Antiretroviral Therapy in Zimbabwe. 37th Annual International Conference on Global Health. 2010.
  • Maponga C; DiFrancesco R; Tooley KM; Jaravani P; Ma Q; Morse ED. Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research In Southern African Countries. 18th International AIDS Conference (AIDS 2010). 2010.
  • DiFrancesco R; Tooley KM; Pande P; Siminski S; Morse ED. HIV Clinical Pharmacology Quality Assurance (CPQA) and Quality Control Program: Current Status and Planning for Expanded Research. 18th International AIDS Conference (AIDS 2010). 2010.
  • DiFrancesco R; Morse ED. Pharmacology Study Conduct in ACTG Protocols. AIDS Clinical Trials Group Annual Meeting. 2010.
  • Tooley KM; Morse ED. Pharmacology Study Conduct in IMPAACT Protocols. International Maternal, Pediatric, and Adolescent AIDS Clinical Trials Group Annual Meeting. 2010.
  • Mudzviti T; Sibanda M; Maponga C; Morse ED; Gavi S. An Evaluation of Cutaneous Adverse Drug Reactions and Antiretroviral Therapy Use in HIV Infected Patients in a Resource Limited Setting. 11th International Workshop on Clinical HIV Pharmacology of HIV Therapy. 2010.
  • Venuto C; Ma Q; Morse ED. Effects of CYP2B6 single nucleotide polymorphism (SNPs) and substance abude on efavirenz (EFV) pharmacokinetics. UB Celebration of Academic Excellence. 2010.
  • Chimhungwe G; DiFrancesco R; Gray G; De Bruyen G; Maartens G; Morse ED. Bioanalysis of Antiretrovirals in Breast Milk Samples from Re-lactation Protocols. Developmental Center for AIDS Research (DCFAR) World AIDS Day Scientific Symposium. 2009.
  • Fehintola F; Ma Q; Zingman B; Reichman R; Fischl M; Gripshover B; DiFrancesco R; Forrest A; Morse ED. Tobacco and Marijuana Uses Significantly Decrease Atazanavir (ATV) Trough Concentrations in HIV Infected Individuals. ICAAC Conference. 2009.
  • Catanzaro LM; Nelson MM; Lliguicota FO; Warrick J; Morse ED. Development and Implementation of Web-based HIV Pharmaceutical Care Continuing Education and Certificate Programs. AJPE. 2008; 72.
  • Coe HV; Catanzaro LM; Lliguicota FO; Morse ED. Development of an Academic Pharmacotherapy Information Center Website as a Resource for Community Healthcare Providers. AJPE. 2008; 72.
  • Slazak EM; Albanese NP; Wrobel MJ; Monte SV; Orlick A; Ambres C; Morse ED. Abstract: Medsense, an academic medication management program in a primary care group. ACCP. 2008.
  • Maponga C; Makadzange T; Ndhlovu C; Morse ED. Collaborative Clinical Pharmacology Research Unit Development in Developing Countries. 2007 International AIDS Society Conference. 2007.
  • Maponga C; DiFrancesco R; Tooley K; Lliguicota F; Morse ED. International Technology Transfer for Establishing Antiretroviral Pharmacology Laboratories in Developing Countries. 2007 International AIDS Society Conference. 2007.
  • Maponga C; Chizanga T; Morse ED. Traditional Medicine Use in HIV-infected Patients in Harare. 2007 International AIDS Society Conference. 2007.
  • Catanzaro LM; Brody PM; Fiebelkorn KD; Felton C; Bellnier T; Morse ED. Integrated Approach to Community Pharmacy Medication Therapy Management (MTM) and Doctor of Pharmacy Experiential Programs.. AJPE. 2007; 71.
  • Slazak EM; Albanese NP; Wrobel MJ; Monte SV; Orlick AE; Ambres CA; Morse ED. MedSense, and Academic Medication Management Program in a Primary Care Group Practice. AACP. 2007.
  • Albanese NP; Coe HV; Snow II; Notaro JC; Morse ED. Pharmacotherapy Management Program: Development of Initial Outcomes in a Multi-Specialty Physician's Group. AACP. 2006.
  • Fiebelkorn KD; Catanzaro LM; Bosinski AM; Brazeau GA; Morse ED; Lliguicota F. Enhancing Quality in Pharmacy Practice by e-Pharmacotherapy Networks in Asthma, HIV and Poison Prevention. AJPE. 2006; 70.
  • Slazak EM; Paolini NM; Broffman G; Morse ED. Evaluation of Patient-Centered Pharmacotherapy Management in a Managed Care Organization. ACCP Annual Meeting. 2005.
  • Slish J; Catanzaro L; Tooley K; Lliguicota F; DiFrancesco R; Morse ED. National HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry. International Workshop on Clinical Pharmacology of HIV Therapy. 2005.
  • Labbe L; Morse ED; Fischl MA; Feinberg J; Collier A; DiCenzo R; Sheiner LB; A. Effect of Co-administration of Efavirenz and Nelfinavir on the Pharmacokinetics of Indinavir. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. 2005.
  • Ma Q; Forrest A; Rosenkranz S; Para M; Adams E; Yaresheski K; Reichman RC; Morse ED; A. Optimal multidrug PK and sampling strategies (OSS) for efavirenz and indinavir. 2005 Annual Meeting of the American Society of Clinical Pharmacology & Therapeutics. 2005.
  • Zack J; A; Forrest A; Ma Q; Rosenkranz S; Para MF; Adams E; Yaresheski K; Reichman RC; Morse ED. Optimal Sparse Pharmacokinetic Sampling Strategies for Multi-Drug Antiretroviral Regimens. Annual Meeting of the American Society for Clinical Pharmacology & Therapeutics. 2005.
  • Chen AL; Forrest A; DiCenzo R; Rosenkranz S; Para MF; Yarasheski KE; Reichman RC; Morse ED. A Pharmacokinetics (PK) Model for Nelfinavir (NFV) and M8 when Co-administered with Amprenavir (APV) and Efavirenz (EFV). 2004 Annual Meeting of the American College of Clinical Pharmacy. 2004.
  • Okusanya O; Forrest A; Rosenkranz S; Para M; Adams E; Yaresheski K; Reichman R; Morse ED; A. Compartmental Analysis of Amprenavir (APV) Pharmacokinetics (pk) including Secondary Peaks. 8th World Congress on Clinical Pharmacology & Therapeutics. 2004.
  • Labbe L; Morse ED; Fischl M; Feinberg J; Collier A; Dicenzo R; Sheiner LB; A. Effect of Co-administration of Nelfinavir and Covariates on the Pharmacokinetics of Indinavir in ACTG 388 Trial. ASCPT. 2004.
  • Maponga C; Reichman RC; Esch L; Hewitt RG; Morse ED. Global Pharmacotherapy Initiative Between Developed and Developing Countries. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. 2002.
  • Magee MH; Forrest A; Shelton M; Para M; Fischl M; Morse ED. An Integrated PK/PD model for Delavirdine (DLV). Clinical Pharmacology & Therapeutics. 2000; 67.
  • Shelton MJ; Adams JM; Hewitt RG; Swick L; Steinwandel C; Morse ED. Antiretroviral use in the era of protease inhibitors. Spring Practice and Research Forum of the American College of Clinical Pharmacy. 1997.
  • Mudd PJ; Adams J; Shelton M; Hewitt R; Cousins S; Hu J; DiFrancesco R; Morse ED. Comparison of proinflammatory cytokine profiles between HIV+ patients and seronegative volunteers. Spring Practice and Research Forum of the American College of Clinical Pharmacy. 1997.
  • Morse ED; Adams JM; Shelton MJ; Hewitt RG; Cordaro jA. Lack of influence of menstrual cycle on zidovudine pharmacokinetics. Clinical Pharmacology & Therapeutics. 1996; 59.
  • Shelton MJ; Adams JM; Hewitt RG; Morse ED. High Frequency of Helicobacter pylori co-infection in HIV-postive subjects with gastric hypoacidity. Pharmacotherapy. 1996; 16.
  • Shelton MJ; Adams JM; Hewitt RG; Morse ED. Reduced delavirdine exposure in HIV-positive subjects with gastric hypoacidity. Pharmacotherapy. 1996; 16.
  • Shelton MJ; Adams JM; Hewitt RG; DeRemer M; DiFrancesco R; Grasela TH; Morse ED. Zalcitabine population pharmacokinetics in HIV-infected outpatients. Pharmacotherapy. 1996; 16.
  • Adams J; Shelton M; Grasela T; Hewitt R; DeRemer M; Morse ED. Prospective evaluation of zalcitabine (ddC) population pharmacokinetics. International Conference on AIDS. 1993; 9.
  • O'Donnell MA; Morse ED; Bartos L; Fluman RA. Comparative blood distribution of zidovudine, atevirdine and an ATV metabolite. Pharmacotherapy. 1993; 13.
  • Shelton M; Portmore A; Reichman RC; DeRemer M; Bartos L; Morse ED. Salivary zidovudine concentrations correlation with plasma. Pharmacotherapy. 1993; 13.
  • Morse ED; Portmore A; O'Donnell A; Bartos L; Plank C; Reichman RC. Prolonged elimination of zidovudine detected by radioimmunoassay. Pharmacotherapy. 1991; 11.
  • Morse ED; Hewitt R; Bartos L; Tousley K; O'Donnell AM; Shelton M; Blair D; Reichman R. Zidovudine assay correlation in patient serum samples RIA vs HPLC. Pharmacotherapy. 1991.
  • O'Donnell AM; Bartos L; Morse ED. Zidovudine distribution into blood components. Pharmacotherapy. 1991.
  • Karki S; Bentley DW; Luzier A; Taylor C; Morse ED. Cefonicid disposition in geriatric patients with bacterial pneumonia. Pharmacotherapy. 1990; 10.
  • Morse ED; Hewitt RG; Reichman RC. Comparative oral disposition of zidovudine in neutropenic AIDS patients and asymptomatic HIV-infected hemophiliacs. Pharmacotherapy. 1990; 10.
  • Morse ED; Ruffino D; Cunningham E; Venuto RC. Reliability of single-dose intraperitoneal vancomycin therapy for gram-positive peritonitis. Pharmacotherapy. 1990; 10.
  • Morse ED; Portmore A; Olson J; Taylor C; Plank C; Reichman RC. Renal excretion of zidovudine and zidovudine-glucuronide during multiple dosing. Clinical Pharmacology & Therapeutics. 1990; 47.
  • Santos P; Morse ED; Korzun W; Venuto RC. Variability of digoxin-like immunoreactive substance among hemodialysis patients. Pharmacotherapy. 1990; 10.
  • Morse ED; Olson J; Portmore A; Taylor C; Plank C; Reichman R. Intravenous and oral pharmacokinetics of zidovudine in hemophilia patients with human immunodeficiency virus infection. International Conference on AIDS. 1989; 5.
  • Morse ED; Taylor C; Olson J; Reichman RC. Oral zidovudine disposition in hemophiliacs. Pharmacotherapy. 1988.
  • Morse ED; Nairn DK; Bertino J; Walshe JJ. Vancomycin degradation products which crossreact with fluorescence polarization imunoassay during peritoneal dialysis. Clinical Pharmacology & Therapeutics. 1987; 41.
  • Morse ED; Apicella MA; Walshe JJ. Absorption of intraperitoneal antibiotics. Clinical Pharmacology & Therapeutics. 1987.
  • Morse ED; Lieveld PE; Apicella MA; Walshe JJ. Intraperitoneal cefamandole kinetics in continuous ambulatory peritoneal dialysis patients with and without peritonitis. Clinical Pharmacology & Therapeutics. 1985; 37.
  • Morse ED; Janicke DM; Apicella MA; Walshe JJ. Individualization of tobramycin dosing during continuous ambulatory peritoneal dialysis. Drug Intelligence & Clinical Pharmacy. 1985; 19.
  • Morse ED; Janicke DM; Cafarell RF; Walshe JJ; Venuto RC; Apicella MA; Jusko WJ. Pharmacokinetics of intraperitoneal moxalactam in CAPD. Drug Intelligence & Clinical Pharmacy. 1984; 18.
See all (43 more)

Professional Memberships:
  • Elected Member, AIDS Clinical Trials Group’s HIV Reservoirs and Viral Eradication Transformative Science Group (ACTG’s Cure TSG) (2015–2017)
  • ACCP Global Conference; Panel Judge (2015)
  • New York State Department of Health AIDS Institute's (AI) Medical Care Criteria Committee (MCCC) (2015–present)
  • AIDS Clinical Trials Group’s HIV Reservoirs and Viral Eradication Transformative Science Group (ACTG’s Cure TSG) (2015–present)
  • Advisory Board Member and Scientific Collaborator, Global Technologies Implementation, You First Services, Inc. (2015–present)
  • External Scientific Advisory Board, Eugene Applebaum College of Pharmacy, Wayne State University (2013–present)
  • AACP Volwiler Research Achievement Award Selection Committee; Member (2012)
  • NIH, National Institute for Allergy and Infectious Diseases; Member, External Advisory Board, Women’s Interagency HIV Study (WIHS) (2012)
  • New York State Department of Health AIDS Institute's Pharmacy Advisory Committee; Member (2012)
  • University of Zimbabwe College of Health Sciences MEPI Award Training Advisory Committee; Member (2011)
  • ACTG Executive Committee; Member (2010)
  • ACTG Pharmacology Specialty Laboratory Core; Director (2010)
  • Center for Human Experimental Therapeutics (CHET), UR CTSA; Member (2010)
  • Steering Committee of the NY HIV Research Centers Consortium; Member (2010)
  • American Society of Nanomedicine; Member (2010)
  • Original Research and Clinical Pharmacy Forum; ACCP Abstract Reviewer (2010)
  • Upstate NY Translational Research Network (UNYTRN), UR CTSA; Co-Director (2010)
  • UNYTE Translational Research Network, University of Rochester CTSA; Co-Director (2010)
  • CTRC Laboratory Sub-Committee; Member (2009)
  • CTSA Steering Committee; Member (2009)
  • CTRC Ambulatory Research Center Sub-Committee; Member (2009)
  • CTRC Bioinformatics Sub-Committee; Chair (2009)
  • CTRC Executive Sub-Committee; Member (2009)
  • CTSA Biomedical Informatics; Key Function Director (2009)
  • FDA Antiretroviral Drugs Advisory Committee (AVDAC); Consultant (2009)
  • NYS Patient Safety Enhancement, New York State Department of Health (2009–present)
  • NYS DOH NYPASE Rural Health Subcommittee; Member (2008)
  • Clinical Research Working Group Committee; Member (2008)
  • NY HIV Research Centers Clinical Research Working Group Committee; Member (2008)
  • NYS DOH NYPASE Technology Subcommittee; Chair (2008)
  • NYS DOH NYPASE Health Literacy Subcommittee; Member (2008)
  • Fellowship Program Peer Review Committee (2007)
  • American Association of Colleges of Pharmacy Reviewer Crystal APPLE Award (2007)
  • Research Advisory Committee; Member (2006–2008)
  • Fellowship Peer Review Committee; Chair (2004)
  • American Academy of HIV Medicine; Member (2003)
  • AACP Accrediatation Standards Review Committee; Member (2002)
  • Fellowship Peer Review Committee; Member (2002)
  • New York Academy of Science; Member (1998)
  • Infectious Disease Specialty Practice Group American Society for Clinical Pharmacology and Therapeutics; Member (1998)
  • American Society for Clinical Pharmacology and Therapeutics (1998–present)
  • Fellowship Accreditation Committee; Member (1995)
  • American College of Clinical Pharmacy; Fellowship Training Certification (1995–present)
  • Task Force on ACPE Accreditation Standards; Member (1994)
  • Board of Pharmaceutical Specialities (2003, 2011 Recertification); Board Certified Pharmacotherapy Specialist (1992–2011)
  • Mid-Winter Annual Meeting; Abstract Reviewer (1992–present)
  • Annual Meeting; Abstract Reviewer (1991–present)
  • New York State College of Clinical Pharmacy; President (1990–1992)
  • International AIDS Society; Member and Abstract Reviewer (1990)
  • Nephrology Section Moderator, Annual Meeting (1990)
  • Selection Committee for Infectious Disease Fellowship; Member (1990)
  • New York State College of Clinical Pharmacy, President (1990)
  • Research Affairs Committee; Member (1990)
  • New York State; Regional Recruiter (1989)
  • Development of New York State Chapter of ACCP; Coordinator (1989)
  • American Society of Hospital Pharmacists (1988–1994)
  • Membership Committee; Member (1988–1989)
  • Selection Committee for Clinical Pharmacokinetics Fellowship; Member (1988)
  • New York State Council of Hospital Pharmacists (1988–present)
  • American College of Clinical Pharmacy; Full Member (1987–2008)
  • Program Committee for Annual Meeting; Member (1987)
  • New York Academy of Science International Society for Immunopharmacology (1986–1992)
  • New York Academy of Science International Society for Immunopharmacology; Member (1986)
  • Midyear Clinical Meeting; Program Chairman (1986–present)
  • New York State Council of Hospital Pharmacists (1985–1989)
  • Continuing Competency Committee; Member (1985)
  • Rho Chi Society (1983–present)
See all (57 more)
Presentations:
  • "Developing a Center for Integrated Global Biomedical Sciences" Pharmacy Practice and Translational Research Seminar, University of Houston College of Pharmacy (2016)
  • "UB Contributions to CFAR and UB Core Concept" CFAR Symposium (2016)
  • "Overview of SUNY-University of the West Indies Collaboration and SUNY GHI Research Project Planning" SUNY Global Health Institute – Global Diabetes Project Planning Meeting (2016)
  • "Center for Integrated Global Biomedical Sciences and UWI Partnership" Launch of the SUNY-UWI Health Research Task Force (2016)
  • "Center for Integrated Global Biomedical Sciences and HRTP Evolution" Launch of NIH Fogarty International Center HIV Research Training Program (HRTP) (2016)
  • "Leveraging Clinical and Translational Science Awards (CTSAs) to Enhance HIV Research Training Programs (HRTPs)" Fogarty HIV Research Training Program Network Meeting (2016)
  • "Diabetes and the Nervous System: Is there a role for the Cannabinoids?" University Diabetes Outreach Programme (UDOP) Annual International Conference (2016)
  • "Inflammation Investigated as a Source of Atazanavir Pharmacokinetic Variability." Conference on Retroviruses and Opportunistic Infections (CROI), CROI, Exposure-Response: Learning and Applying to Improve Safety and Efficacy (2016)
  • "Clinical and Translational Research: Global Health" SUNY Academic Industry Roundtable (AIR) (2016)
  • "Design and implementation of an international advanced pharmacy practice experience (APPE) rotation in a resource-limited setting with a focus on HIV/AIDS treatment and education: Harare, Zimbabwe" American Society of Health-Systems Pharmacists (ASHP) Clinical Midyear Meeting, ASHP (2015)
  • "Adherence assessment techniques in adolescents receiving a protease inhibitor based antiretroviral therapy treatment regimen in a resource limited setting" Conference on Clinical Pharmacy, ACCP (2015)
  • "Global Therapeutics Development and Clinical Health Informatics Implementation" SUNY Academic Industry Roundtable (AIR), SUNY (2015)
  • "HIV Reservoirs and Viral Eradication Transformative Science Group" Center for Aids Research (CFAR) and CTU Retreat, University of Rochester Medical Center (2015)
  • "Issues in U.S. Based International Research - Fostering Development of Clinical Pharmacy Research and Scholarship Throughout the World" ACCP Global Conference on Clinical Pharmacy (2015)
  • "Personalized Medicine and the Consumer: What You Need to Know and Understand in 2015" Alumni Panel, University at Buffalo, SUNY (2015)
  • "ACTG Laboratory Network Meeting" ACTG Annual Meeting (2015)
  • "Advances in Hepatitis C Treatment" Society of Infectious Diseases Pharmacists (SIDP) (2014)
  • "New Fogarty HIV Research Training Programs for Capacity Building. Global HIV Clinical Pharmacology Capacity Building and Implementation Research" WCP 2014 (2014)
  • "Zimbabwe Capacity Building for HIV Implementation Research" Global Implementation Conference 2013 (2013)
  • "Translational Pharmacoinformatics: Developing an Integrated Central Resource for Planning HCV Drug Interactions Research" 10th Annual HCV DrAG (2013)
  • "A Randomized, Double-blind, Phase 1b Study of the HCV Entry Inhibitor ITX 5061 in Treatment-naive, HCV monoinfected Adults: ACTG A5277" Conference on Retroviruses and Opportunistic Infections(CROI). (2013)
  • "Breakthroughs and Opportunities for the Next Generation of Pharmacists" 2nd Annual Conference, Mapping New Visions, Quest for Pharmaceutical Excellence., Zimbabwe Pharmaceutical Students Association (2013)
  • "Genome-wide Association Study of Atazanavir (ATV) Pharmacokinetics (PK) and Indirect Hyperbilirubinemia (HBR)." Conference on Retroviruses and Opportunistic Infections(CROI) (2013)
  • "Utilizing Health Information Technology to Perform Patient Safety Medication Reviews in a Patient Centered Medical Home Model for Oncology - A Pilot Study" American Society of Health System Pharmacists Midyear Meeting (ASHP) (2012)
  • "Nanomedicine and Translational Pharmacology: Considerations for HIV and TB" Division of Acquired Immunodeficiency Syndrome (DAIDS)/ National Institute of Allergy and Infectious Diseases (NAIDS)/ National Institute of Health(NIH) Meeting, NIH (2012)
  • "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" XIX International AIDS Conference (IAS AIDS 2012), IAS AIDS (2012)
  • "Atazanavir Pharmacokinetics and Efficacy and Safety Outcomes by Sex in AIDS Clinical Trials Group Study 5202 (A5202)" ACTG Conference, ACTG (2012)
  • "Clinical PharmacologyQuality Assurance (CPQA) Program: Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories" XIX International AIDS Conference (AIDS/IAS 2012), IAS AIDS (2012)
  • "Drug Interactions and Challenges to Designing Combination HIV/HCV Protocols with new Directly Acting HCV Antivirals and Antiretrovirals" ACTG Conference, ACTG (2012)
  • "Informatics-Based Drug Interactions Database for Clinical Protocols" XIX International AIDS Conference (IAS AIDS 2012), IAS AIDS (2012)
  • "Tenofovir Plasma Pharmacokinetics in AIDS Clinical Trials Group Study A5202" XIX International AIDS Conference (AIDS/IAS 2012), IAS AIDS (2012)
  • "The 3rd Annual Workshop on Global HIV Clinical Pharmacology Capacity Building and Implementation Research" XIX International AIDS Conference, IAS AIDS (2012)
  • "International Pharmacotherapy Education and Research Initiatives (IPERI)" University at Buffalo Department of Social and Preventive Medicine Seminar, University at Buffalo (2012)
  • "Pharmacokinetic Considerations for Drug Interactions during HCV DAA Development" AIDS Clinical Trials Group Scientific Retreat - Hepatitis Transformative Science Group, NIH AIDS Clinical Trials Group (2012)
  • "Use of Opportunistic Infection (OI) Prophylaxis between Blacks and Whites with HIV/AIDS" Infectious Diseases Society of America (2011)
  • "Autobiographical memory specificity and the persistence of depression in HIV-positive patients: Rumination and social problem solving skills as mediators." European Association for Behavioural and Cognitive Therapies (2011)
  • "Center for International Pharmacotherapy Education and Research Initiatives (IPERI)" Presidential Inaugural Week - University at Buffalo Global Fair, University at Buffalo (2011)
  • "An Assessment of the Variability of Labeling and Counseling Information of Selected Herbal Medications Marketed for HIV and AIDS in Harare, Zimbabwe" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Global Challenges to HIV Clinical Pharmacology Research" Educational Meeting - Catherine McAuley Education and Research Centre, Mater Misericordiae University Hospital (2011)
  • "Global Strategy for Quality Assessment of Clinical Pharmacology Research Laboratories" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Patient Perceptions, Knowledge, and Practices of the Role of Nutrition in HIV/AIDS Management in a Resource Limited Setting" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Prevalence of heterosexual anal intercourse and oral sex among high risk populations in Harare, Zimbabwe" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Quality Assurance Initiative for Clinical Pharmacology Laboratory Development in Resource Limited Countries" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Quality Assurance of Antiretroviral Assays in Human Biofluids and Tissues during HIV Prevention and Treatment Research" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Reproducibility of Antiretroviral Proficiency Testing" 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, International AIDS Society (2011)
  • "Pharmacogenetics of low plasma efavirenz (EFV) concentrations in AIDS Clinical Trials Group (ACTG) studies: Analysis NWCS 301" 12th International Workshop on Clinical Pharmacology of HIV Therapy (2011)
  • "Pharmacokinetics of NNRTI Efavirenz among HIV Infected Ugandans" 12th International Workshop on Clinical Pharmacology of HIV Therapy (2011)
  • "Upstate New York Translational Research Network" Clinical and Translational Science Institute Scientific Symposium, University of Rochester (2011)
  • "Establishing an International Network for Using Health Information Technology in HIV/TB Medication Management Research" AMIA Summit on Clinical Research Informatics (CRI), American Medical Informatics Association (2011)
  • "The Age of Personalized Oncology Therapies - Impact on All Oncology Stakeholders" Association for Value-Based Cancer Care (2011)
  • "Global Translational Pharmacology Strategy for Drug Development and Research for HIV and Tuberculosis Treatment" , NIH/NIAID (2011)
  • "Pharmacogenetics of Change in Calculated Creatinine Clearance with Regimens Containing Tenofovir Disoproxil Fumarate (TDF) in AIDS Clinical Trials Group (ACTG) Study A5202" 18th Conference on Retroviruses and Opportunistic Infections (2011)
  • "Whole Genome Association Study (GWAS) of Virologic Failure with Efavirenz (EFV)- and/or Abacavir (ABC)-Containing Regimens in AIDS Clinical Trials Group (ACTG) Studies" 18th Conference on Retroviruses and Opportunistic Infections (2011)
  • "A Comprehensive Quality Assurance Program for Global HIV/AIDS Clinical Pharmacology Research" DCFAR 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
  • "Development of a Web-based Drug Interaction Database and Utility for HIV/AIDS Research Protocols" DCFAR 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
  • "Establishing A Health Information Technology Network for HIV/TB Medication Management Research" DCFAR 2nd Annual World AIDS Day Scientific Symposium, University of Rochester (2010)
  • "Interindividual Variability of ABCB1 Expression in Peripheral Blood Mononuclear Cells from HIV-Infected Patients" 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2010)
  • "Establishing an AIDS International Training and Research Program (AITRP) to Increase Capacity for HIV Clinical Pharmacology Research in Southern African Countries" XVII International AIDS Conference (AIDS 2010) (2010)
  • "HIV Clinical Pharmacology Research in Southern African Countries" XVIII International AIDS Conference (2010)
  • "Pharmaceutical Safety Initiative: Enhancing Patient Safety with Information Technology and Biomedical Informatics" Pharmacy Safety Forum, New York Department of Health - Patient Safety Center (2010)
  • "Pharmacology Study Conduct in ACTG Protocols" AIDS Clinical Trials Group Annual Meeting, AIDS Clinical Trials Group (2010)
  • "Pharmacology Study Conduct in IMPAACT Protocols" International Maternal, Pediatric, and Adolescent AIDS Clinical Trials Group Annual Meeting (2010)
  • "An Evaluation of Cutaneous Adverse Drug Reactions and Antiretroviral Therapy Use in HIV Infected Patients in a Resource Limimted Setting" 11th International Workshop on Clinical HIV Pharmacology of HIV Therapy (2010)
  • "Effects of CYP2B6 single nucleotide polymorphisms (SNPs) and substance abuse on efavirenz pharmacokinetics" UB Celebration of Academic Excellence, University at Buffalo (2010)
  • "Developing an International Health Information Technology Network for HIV Medication Management Research" NY HIV Research Centers Consortium 2010 Scientific Conference (2010)
  • "Bioanalysis of Antiretrovirals in Breast Milk Samples from Re-lactation Protocols" DCFAR World AIDS Day Scientific Symposium, University of Rochester (2009)
  • "Bioanalysis of Antiretrovirals in Breast Milk Samples from Re-lactation Protocols" Developmental Center for AIDS Research (DCFAR) World AIDS Day Scientific Symposium, DCFAR (2009)
  • "UB 2020 Strategic Strength Planning: Information and Computer Technology - Potential Interactions with Center of Excellence in Bioinformatics and Life Sciences" School of Computer Science and Engineering (CSE) Information and Computing Technology Workshop, University at Buffalo (2009)
  • "Implementing a Bioinformatics and Medication Management Research Network" University of Rochester Clinical and Translational Research Center (RCTRC) Seminar Series (2009)
  • "Successful Use of Standard Lopinavir/r Dosing (Tablets) in a Cohort of HIV-infected Pregnant Women" IAPAC (2009)
  • "The impact of memory specificity and emotional distress on self-reported treatment adherence among HIV+ patient" Autobiographical Memory Meeting (2009)
  • "Update on pharmacotherapy for pediatric HIV infection" 13th Asian Pacific Congress of Pediatrics (2009)
  • "Effects of CYP2B6 single nucleotide polymorphisms and substance abuse on efavirenz pharmacokinetics" 49th ICAAC, ASM (2009)
  • "Inter-individual variability of atazanavir plasma concentrations in HIV patients" 49th ICAAC, ASM (2009)
  • "Relationship between CYP3A5 single nucleotide polymorphisms and protease inhibitor trough concentrations in HIV+ patients during therapeutic drug monitoring" 49th ICAAC, ASM (2009)
  • "Tobacco and marijuana uses significantly decrease atazanavir trough concentrations in HIV infected individuals" 49th ICAAC, ASM (2009)
  • "Implementing a Comprehensive HIV Clinical Pharmacology Quality Assurance Program" 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (2009)
  • "Implementing a Comprehensive HIV Clinical Pharmacology Quality Assurance Program" 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention (2009)
  • "Continuity of HIV/AIDS Pharmacotherapy through an Integrated Multidisciplinary Immunodeficiency Services Medication Reconciliation Program" IAPAC HIV Treatment (2009)
  • "High Performance Liquid Chromatographic Method for the Analysis of Dilsufram and its metabollites in Human Plasma" University at Buffalo Poster Day, Department of Pharmaceutical Sciences (2009)
  • "Therapeutic Drug Monitoring of Antiretrovirals" Infectious Disease Pharmacotherapy Symposium (2009)
  • "Clinical Pharmacology Quality Assurance Update" AIDS Clinical Trials Group Meeting (2009)
  • "Comparison of antiretroviral pharmacokinetics and clinical monitoring parameters in HIV-infected patients with and without substance abuse" 16th Conference on Retroviruses and Opportunistic Infections (2009)
  • "Clinical Pharmacology Quality Assurance Update" AIDS Clinical Trials Group Meeting (2008)
  • "Clinical and Translational Pharmacogenomics: Integrating a Seminar Program with UndergraduatePharmacogenomics Research" ACCP Annual Meeting, American College of Clinical Pharmacy (2008)
  • "International Collaboration in HIV/AIDS Pharmacotherapy Research and Training" 2008 Society of Infectious Diseases Pharmacists (SIDP) Annual Meeting (2008)
  • "Implementation of a Bioinformatics and Medication Management Research Network to Increase Medication Safety" Framing for Change - WNY Alliance for Person-Cent Care (2008)
  • "Development and Implementation of Web-based HIV Pharmaceutical Care Continuing Education and Certificate Programs" ACCP/AFPC Annual Meeting (2008)
  • "Development and Implementation of Web-based HIV Pharmaceutical Care Continuing Education and Certificate Programs" American Association of Colleges of Pharmacy Annual Meeting (2008)
  • "Application to ACTG Pharmacology Studies and Data Management" Frontier Science and Technology Research Foundation (2008)
  • "Application to ACTG Pharmacology Studies and Data Management" , Frontier Science and Technology Research Foundation (2008)
  • "Separation of Triphosphorylated Nucleoside Reverse Transcriptase Inhibitors by Capillary Electrophoresis Using Field-Amplified Sample Stacking (CE-FASS)" 26th Annual Graduate Students' Symposium, Chemistry Graduate sSudents, SUNY-Buffalo (2008)
  • "Effect of CYP3A5 polymorphisms on atazanavir and lopinavir trough concentrations in HIV-infected substance abusers" 9th International Workshop on Clinical Pharmacology of HIV Therapy (2008)
  • "Integrating Noninvasive Liver Diagnostic Approaches with Drug Development for Hepatitis B and/or C" AIDS Clinical Trials Group Meeting (2008)
  • "Medication Management Research Network" Department of Health, Department of Health (2008)
  • "Pharmacogenetics of Plasma Drug Exposure and Treatment Outcomes with Efavirenz (EFV)-Containing Regimens: An AIDS Clinical Trials Group (ACTG) Study" 15th Conference on Retroviruses and Opportunistic Infections (CROI 2008) (2008)
  • "Integrating Noninvasive Liver Diagnostic Approaches with Drug Development for Hepatitis B and/or C" Adult AIDS Clinical Trials Group (2007)
  • "An Appropriate Structural and Population Pharmacokinetic (PK) Model for Atazanavir (ATV)" ICAAC (2007)
  • "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" ICAAC (2007)
  • "Integrated Approach to Community Pharmacy Medication Therapy Management (MTM) and Doctor of Pharmacy Experiential Programs" AACP, AACP (2007)
  • "International Technology Transfer for Establishing Antiretroiral Pharmacology Laboratories in Developing Countries" 4th International AIDS Society Conference (2007)
  • "MedSense, an Academic Medication Management Program in a Primary Care Group Practice" AACP Annual Meeting, AACP (2007)
  • "Overview: Translational Pharmacology Core" NYS Center of Excellence in Bioinformatics and Life Sciences (2007)
  • "Pharmacologic Factors and Individualization of HIV Treatment" , Boston Medical Center (2007)
  • "Determination of HIV Protease Inhibitors in Plasma by HPLC" The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (PITTCON'2007) (2007)
  • "Nucleoside Reverse Transcriptase Inhibitors in Peripheral Blood Mononuclear Cells from Human Whole Blood by Capillary Electrophoresis and HPLC" The Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (PITTCON'2007) (2007)
  • "Therapeutic Drug Monitoring and Inhibitory Quotients in HIV-Infected Substance Users and Non-substance Users Receiving HIV-1 Protease Inhibitors" CROI 2007 (2007)
  • "Application of the ACTG Drug-Drug Interaction Table to Subject Enrollment and Monitoring" , AIDS Clinical Trials Group (2006)
  • "Application to ACTG Pharmacology Studies and Data Management" AIDS Clinical Trials Group Meeting (2006)
  • "Revised Pharmacology Plan for A5202: A Phase IIB, Randomized, Trial of Open-Label Efavirenz or Atazanavir with Ritonavir in Combination with Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects" AIDS Clinical Trials Group Meeting (2006)
  • "Establishing a Clinical Pharmacy Fellowship Program" Annual Meeting of the American College of Clinical Pharmacy, American College of Clinical Pharmacy (2006)
  • "Pharmacologic Factors and Individualization of HIV Treatment" (2006)
  • "Translational Aspects of HIV Treatment" City Wise Grand Rounds, Erie County Medical Center (2006)
  • "CYP3A5 polymorphisms in HIV-infected substance users and nonusers during therapeutic drug monitoring" 49th Annual Meeting of ICAAC (2006)
  • "Therapeutic Drug Monitoring of Antiretrovirals" Visiting Professor Lecture Series, Food & Drug Administration (2006)
  • "HIV Adherence-Pharamacology Unit Establishes Regional Pharmacotherapy Review Program" XVI International AIDS Conference (2006)
  • "Pharmacotherapy Management Program: Development and Initial Outcomes in a Multi-specialty Physicians Group" AACCP (2006)
  • "Analysis of Phosphorylated Nucleosides Reverse Transcriptase Inhibitors in Human Plasma" 30th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC'2006) (2006)
  • "ACCP Peer Review Process for Clinical Research Fellowship Programs" Annual Meeting of the American College of Clinical Pharmacy, American College of Clinical Pharmacy (2006)
  • "National Institutes of Health Transforming Event: Clinical and Translational Science Awards" SUNY Translational Research Conference (2006)
  • "The Impact of Life Stress on HIV Treatment Adherence-Preliminary Analysis" NIMH/IAPAC International Conference on HIV Treatment Adherence (2006)
  • "Atazanavir/ritonavir 300/100mg (ATV/r) Therapeutic Drug Monitoring (TDM) in HIV-infected Patients with and without substance abuse" CROI 2006 (2006)
  • "MDR1 Polymorphisms, Therapeutic Drug Monitoring, Protease Inhibitors" CROI (2006)
  • "MDR1 Single Nucleotide Polymorphisms in HIV-infected Substance Users and Nonusers during Therapeutic Drug Monitoring" 45th Annual ICAAC (2005)
  • "National HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry" ASHP Clinical Midyear Meeting (2005)
  • "Planning for Future TDM Research" Pharmacology Committee, National Institute of Health AIDS Clinical Trials Group Retreat (2005)
  • "Therapeutic Drug Monitoring (TDM) in patients Co-Infected with HIV and Hepatitis C (HCV)" 45th Annual ICAAC (2005)
  • "Evaluation of Patient-Centered Pharmacotherapy Management in a Managed Care Organization" ACCP Annual Meeting, ACCP (2005)
  • "HIV-Adherence Pharmacotherapy and Clinical Research" American College of Clinical Pharmacy Annual Meeting (2005)
  • "HIV-Adherence Pharmacotherapy and Clinical Research" American College of Pharmacy Annual Meeting (2005)
  • "Therapeutic Drug Monitoring (TDM) in patients Co-Infected with HIV and Hepatitis C (HCV)" American College of Clinical Pharmacy Annual Meeting (2005)
  • "Antiretroviral Therapeutic Drug Monitoring" Annual HIV Education Program, California Kaiser Permanante (2005)
  • "Comprehensive Pharmacologic Evaluation for Interdisciplinary Management Strategies" Treatment and Management of HIV Infection in the United States Conference (2005)
  • "Comprehensive Pharmacologic Evaluation for Interdisciplinary Management Strategies" Treatment and Management of HIV Infection in the United States Conference (2005)
  • "HIV Adherence Pharmacology Unit Coordinates Pharmacotherapy and Clinical Research" Treatment and Management of HIV Infection in the United States Conference (2005)
  • "HIV Adherence Pharmacology Unit Coordinates Pharmacotherapy and Clinical Research" Treatment and Managemnt of HIV Infection in the Unites States Conference (2005)
  • "Integrating TDM and Resistance Tests" , Antiviral Treatment Center, University of California (2005)
  • "Integrating TDM and Resistance Tests" UCSD Division of Infectious Disease Seminar Program (2005)
  • "Therapeutic Drug Monitoring (TDM) in HIV/Hepatitis C (HCV) Patients" Treatment and Management of HIV Infection in the United States Conference (2005)
  • "Therapeutic Drug Monitoring (TDM) in HIV/Hepatitis C (HCV) Patients" Treatnent and Management of HIV Infection in the United States Conference (2005)
  • "Antiretroviral Drug Interactions and Therapeutic Drug Monitoring" , Montefiore Medical Center (2005)
  • "HIV-Adherence Pharmacology Unit Coordinates Pharmacotherapy, Promotes Clinical Research and Facilitates the Medication Reconciliation Process" NIMH/IAPAC International Conference on HIV Treatment Adherence (2005)
  • "Compartmental Analysis of Saquinavir Pharmacokinetics" Annual Meeting of the Amercian Society for Clinical Pharmacology & Therapeutics (2005)
  • "Antiretroviral Pharmacology" AIDS Program, Montefiore Medical Center (2004)
  • "Buprenorphine does not alter efavirenz pharmacokinetics" 66th Annual Scientific Meeting on the College on Problems of Drug Dependence (2004)
  • "The Utilization of Mass Spectrometry in Cilnical HIV Antiviral Therapy Management" 52nd American Society for Mass Spectrometry Conference (2004)
  • "The Utilization of Mass Spectrometry in Clinical HIV Antiviral Therapy Management" 52nd American Society for Mass Spectrometry Conference (2004)
  • "Efavirenz and a Second Protease Inhibitor" 9th CROI (2004)
  • "Effect of co-administration of nelfinavir and covariates on the pharmacokinetics of indinavir in ACTG 388" 2004 ASCPT Meeting (2004)
  • "Three-way Pharmacokinetic Interaction Among Amprenavir, Efavirenz and a Second Protease Inhibitor" 9th CROI (2004)
  • "Effect of Co-Administration of Nelfinavir and Covariates on the Pharmacokinetics of Indinavir in ACTG 388" 2004 ASCPT Meeting (2004)
  • "The impact of an adherence program on obtaining interpretable therapeutic drug monitoring (TDM) concentrations of antiretrovirals (ARVs)" 2nd International Conference on Adherence to Antiretroviral Therapy (2003)
  • "Clinical Application of Therapeutic Drug Monitoring of Antiretrovirals" American College of Clinical Pharmacy Annual Meeting (2003)
  • "Clinical application of therapeutic drug monitoring of antiretrovirals" American College of Clinical Pharmacy Annual Meeting (2003)
  • "Capillary Separation to Characterize Protease Inhibitor Protein Binding" 43rd ICAAC (2003)
  • "Methadone Increases Ritonavir Exposure When Administered Alone But Not Lopinavir/Ritonavir Combination" 43rd ICAAC (2003)
  • "Methadone increases ritonavir exposure when administered alone but not lopinavir/ritonavir combination" 43rd ICAAC (2003)
  • "Methadone increases ritonavir exposure when administered alone but not lopinavir/ritonavir combination" 43rd ICAAC (2003)
  • "Drug Interactions Between Antiretrovirals and Hormone Contraceptives" NIH AIDS Clinical Trials Group Meeting (2003)
  • "Establishing an Adherence-Pharmacology Unit in developing countries" International AIDS Society (2003)
  • "Therapeutic Drug Monitoring of Antiretrovirals" Infectious Disease Research Conference, Brigham and Women's Hospital, Harvard University (2003)
  • "HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry: Attaining Compliance with Clinical Laboratory Improvement Act (CLIA) and the Health Insurance Portability and Acountability Act (HIPAA)" Making a Difference (MAD) Infectious Disease Pharmacotherapy Conference (2003)
  • "HIV Drug Interaction and Antiretroviral (ARV) Therapeutic Drug Monitoring (TDM) Registry: Attaining Compliance with Clinical Laboratory Improvement Act (CLIA) and the Health Insurance Portability and Accountabiity Act (HIPAA)" Making a Difference (MAD) Infectious Disease Pharmacotherapy Conference (2003)
  • "Therapeutic Drug Monitoring of Antiretrovirals" International Association of HIV and AIDS Caregivers (2003)
  • "Integrating HIV Resistance Tests with Antiretroviral Therapeutic Drug Monitoring" Gilead Life Sciences Research Conference (2003)
  • "Integrating HIV Resistance Tests with Antiretroviral Therapeutic Drug Monitoring" Infectious Disease Research Conference, Stanford University (2003)
  • "Resistance Tests and Drug Concentrations: Applications to Pediatric HIV Therapy" Pediatric Immunology Research Conference, University of Miami (2003)
  • "HIV Drug Interaction and Antiretroviral Therapeutic Drug Monitoring Registry: Attaining compliance with CLIA and HIPAA" 4th International Workshop on Clinial Pharmacology of HIV Therapy (2003)
  • "Promoting adherence to therapy using lay community volunteers: experience from urban Zimbabwe" 4th International Workshop on Clinical Pharmacology of HIV Therapy (2003)
  • "Transitioning an established Adherence Pharmacology Unit to developing countries" 4th International Workshop Clinical Pharmacology of HIV Therapy (2003)
  • "Antiretroviral Proficiency Testing Program for the Adult AIDS Clinical Trials Group (AACTG) Pharmacology Laboratory Network" 10th Conference on Retroviruses and Opportunistic Infections (CROI) (2003)
  • "Effect of Efavirenz on the Pharmacokinetics of Nelfinavir (NFV) and M8 in Na‹ve, HIV-Infected Patients Receiving Long-term HAART Therapy" 10th Conference on Retroviruses and Opportunistic Infections (CROI) (2003)
  • "Capillary Electrophoresis for the Determination of Unbound Protease Inhibitors" NERCDG General Meeting (2002)
  • "Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients" Infectious Disease Society of America Meeting (2002)
  • "Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients" Infectious Disease Society of America Meeting (2002)
  • "Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients" Infectious Disease Society of America Meeting (2002)
  • "Reverse Phase High Performance Liquid Chromatography method for the Analysis of Lopinavir and Ritonavir in Heparinized Human Plasma" NERCDG General Meeting (2002)
  • "Therapeutic Drug Monitoring for HIV-infected Patients During Salvage Therapy" Infectious Disease Research Conference, Columbia University (2002)
  • "Development of an HIV Drug Interactions and Antiretroviral Therapeutic Drug Monitoring Registry" 3rd International Workshop on Clinical Pharmacology of HIV Therapy (2002)
  • "Development of an HIV Drug interactions and Antiretroviral Therapeutic Drug Monitoring Registry" 3rd International Workshop on Clinical Pharmacology of HIV Therapy (2002)
  • "Development of an HIV Drug Interations and Antiretroviral Therapeutic Drug Monitoring Registry" 3rd International Workshop on Clinical Pharmacology of HIV Therapy (2002)
  • "Global Pharmacotherapy Initiative Between Developed and Developing Countries" 3rd International Workshop on Clinical Pharmacology of HIV Therapy (2002)
  • "Global Pharmacotherapy Initiative Between Developed and Developing Countries" 3rd International Workshop on Clinical Pharmacology of HIV Therapy (2002)
  • "Designing Sparse Sampling Approaches to Optimize Indinavir (IDV) Sampling Times" 41st ICAAC (2001)
  • "Designing Sparse Sampling Approaches to Optimize Indinavir (IDV) Sampling Times" 41st ICAAC (2001)
  • "Designing Sparse Sampling Approaches to Optimize Indinavir (IDV) Sampling Times" 41st ICAAC (2001)
  • "Lack of effect of methadone (MET) on the Pharmacokinetics (PK) of Delavirdine (DLV) and N-Delavirdine (NDLV)" 41st ICAAC (2001)
  • "Lack of Effect of Methadone (MET) on the Pharmacokinetics (PK) of Delavirdine (DLV) and N-Delavirdine (NDLV)" 41st ICAAC (2001)
  • "Lack of effect of methadone (MET) on the Pharmacokinetics of Delavirdine (DLV) and N-Delavirdine (NDLV)" 41st ICAAC (2001)
  • "Therapeutic Drug Monitoring in HIV Patients" Infectious Disease Research Conference, VA Hospital (2001)
  • "Advances in HIV Drug Monitoring" Jackson Memorial Hospital Meeting (2001)
  • "Advances in HIV Pharmacology: Therapeutic Drug Monitoring" Pioneer Valley HIV Providers Meeting (2001)
  • "Advances in HIV Pharmacology" Human Subjects Protection Workshop (2001)
  • "Comparing Intensive and Sparse Sampling for Estimating the Population Pharmacokinetics (PK) of Indinavir (IDV) in Efavirenz (EFV) - Containing Regimens" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "Comparing Intensive and Sparse Sampling for Estimating the Population Pharmacokinetics (PK) of Indinavir (IDV) in Efavirenz (EFV) - Containing Regimens" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "Comparing Intensive and Sparse Sampling for Estimating the Population Pharmacokinetics (PK) of Indinavir (IDV) in Efavirenz (EFV)-Containing Regimens" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "High Performance Liquid Chromatography Method for Simultaneous Measurement of Five Protease Inhibitors Plus Efavirenz" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "High Performance Liquid Chromatography Method for Simultaneous Measurement of Five Protease Inhibitors Plus Efavirenz" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "High Performance liquid Chromatography Method for Simultaneous Measurement of Five Protease Inhibitors Plus Efavirenz" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "Intensive Adherence Interventions Improve Virologic Response to Antiretroviral Therapy (ART)" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "Intensive Adherence Interventions Improve Virologic Response to Antiretroviral Therapy (ART) in Treatment Naive Patients" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "Itensive Adherence Interventions Improve Virologic Responseto Antiretroviral Therapy (ART) in Treatment of Naive patients" 8th Conference on Retroviruses and Opportunistic Infections (2001)
  • "Using LCMS for Developing Methods to Analyze Antiviral Drug Species of Current Interest" NERCDG General Meeting (2000)
  • "Adherence as a Determinant of Virologic Response to Potent Protease Inhibitor Therapy" Annual Meeting of the American College of Clinical Pharmacy, American College of Clinical Pharmacy (1999)
  • "Human Immunodeficiency Virus Optimizing Pharmacotherapy Management, Making a Difference - Trends in Infectious Disease Pharmacotherapy" 2nd Annual Conference of Infectious Diseases Pharmacotherapy (1999)
  • "Therapeutic Drug Monitoring: Application to Trial Design in Heavily Pre-Treated Patients" Challenges of Clinical Design in Evaluating HIV Antiretroviral Use in Heavily Pre-Treated Patients Conference (1999)
  • "Development of a therapeutic drug monitoring service for HIV protease inhibitors in an ambulatory care clinic" International Congress on Clinical Pharmacy (1999)
  • "Development of a therapeutic drug monitoring service for HIV protease inhibitors in an ambulatory care clinic" International Congress on Clinical Pharmacy (1999)
  • "Doctoral clerkship opportunities in a Pharm D. candidate-operated medication adherence clinic in an ambulatory care HIV setting" International Congress on Clinical Pharmacy (1999)
  • "Medical imaging an underdeveloped area of pharmacy practice" International Congress on Clinical Pharmacy (1999)
  • "Continued Lamivudine (3TC) vs. Delavirdine (DLV) in Combination with Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Patients" 6th Conference on Retroviruses and Opportunistic Infections (1999)
  • "Continued lamivudine (3TC) vs. delavirdine (DLV) in combination with indinavir (IDV) and zidovudine (ZDV) or stavuine (d4T) in 3TC-experienced patients" 6th Conference on Retroviruses and Opportunistic Infections (1999)
  • "Continued lamivudine vs delavirdine in combination with indinavir (IDV) and zidovudine (ZDV) or stavudine in 3TC-experienced patients" 6th Conference on Retroviruses and Opportunistic Infections (1999)
  • "Randomized trial of abacavir (ABC) in combination wit indinavir (IDV) and efavirenz (EFV) in HIV-infected patients with nucleoside analog experience (NRTI)" 6th Conference on Retroviruses and Opportunistic Infections (1999)
  • "The impact of patient-reported adherence with antiretroviral therapy on virologic response" 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (1998)
  • "Computerization facilitates clinical decision making by integrating medication profiles, adherence and surrogate markers in real time" 12th World AIDS Conference (1998)
  • "HIV Pharmaceutical care specialist (PCS) an alternative model of care for patients with HIV" 12th World AIDS Conference (1998)
  • "Medication adherence enhancement after viral genotyping in HIV+ patients failing highly active antiretroviral therapy (HAART)" 12th World AIDS Conference (1998)
  • "Relationship between delavirdine (DLV) plasma levels, HIV RNA responses and DLV resistance during combination therapy zidovudine (ZDV) and didanosine (ddl)" XII International Conference on AIDS (1998)
  • "Relationship between delavirdine plasma levels, HIV RNA responses and DLV resistance during combination therapy with zidovudine, and didanosine" International Conference AIDS (1998)
  • "Delavirdine mesylate pharmacokinetics during combination therapy with ritonavir" (1998)
  • "Helicobacter pylori serology, not ethnic group is primary determinant of gastric pH in HIV+ subjects" 5th Conference on Retroviruses and Opportunistic Infections (1998)
  • "Indinavir pharmacokinetics and menstrual cycle physiology" 5th Conference on Retroviruses and Opportunistic Infections (1998)
  • "Ritonavir pharmacokinetics during combination therapy with delavirdine" (1998)
  • "Comprehensive cytokine profiles in renal transplant recipients treated for cytomegalovirus infection" 30th Annual Meeting of the American Society for Nephrology (1997)
  • "Ganciclovir pharmacokinetics and cytokine profiles in renal transplant patients with cytomegalovirus infection" 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (1997)
  • "Previous Infection with Helibacter pylori is the Primary Determinant of Spontaneous Gastric Hypoacidity in Human Immunodeficiency Virus-Infected Outpatients" 37th Interscience Conference on Antimicrobial Agents adn Chemotherapy (1997)
  • "Real-time Pharmacology Monitoring in ACTG trials" Plenary, AIDS Clinical Trials Group, AIDS Clinical Trials Group (1997)
  • "Cytokine profiles in renal transplant patients with cytomegalovirs infection" 15th Annual Scientific Meeting of the American Society of Transplant Physicians (1997)
  • "Ganciclovir pharmacokinetics in renal transplant patients with cytomegalovirus infection" 15th Annual Scientific Meeting of the American Society of Transplant Physicians (1997)
  • "Antiviral use in the era of protease inhibitors" 1997 Spring Practice and Research Forum of the American College of Clinical Pharmacy (1997)
  • "Comparison of proinflammatory cytokine profiles between HIV+ patients and seronegative volunteers" 1997 Spring Practice and Research Forum of the American College of Clinical Pharmacy (1997)
  • "Epidemiology of Helicobacter pylori in asymptomatic HIV+ patients" 36th ICAAC (1996)
  • "High frequency of Helicobacter pylori co-infection in HIV-postiive subjets with gastric hypoacidity" ACCP 1996 Winter Practice and Research Forum (1996)
  • "Lack of influence of menstrual cycle on zidovudine pharmacokinetics" ACCP 1996 Winter Practice and Research Forum (1996)
  • "Reduced delavirdine exposure in HIV-positive subjects with gastric hypoacidity" ACCP 1996 Winter Practice and Research Forum (1996)
  • "Zalcitabine population pharmacokinetics in HIV-infected outpatients" ACCP 1996 Winter Practice and Research Forum (1996)
  • "Acidification strategies in HIV+ subjects with gastric hypoacidity" XI International Conference on AIDS (1996)
  • "In vitro studies of drug-drug protein binding displacement with delavirdine mesylate" XI International Conference on AIDS (1996)
  • "Interleukin-8 Assay validation and detection in HIV-infected patients" XI International Conference on AIDS (1996)
  • "Plasma protein binding of delavirdine in HIV-infected patients in ACTG 260" XI International Conference on AIDS (1996)
  • "Effects of Helicobacter pylori treatment on gastric pH and delavirdine pharmacokinetics in HIV+ patients with gastric hypoacidity" Sigma XI Student Research Competition (1996)
  • "Gastric acidification increases DLV mesylate exposure in HIV+ subjects with gastric hypoacidity" 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (1996)
  • "Lack of influcence of menstrual cycle on zidovudine pharmacokinetics" 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (1996)
  • "Colony Stimulating Factors" 1996 Pharmacy Visiting Faculty Update Meeting, University of Wisconsin at Madison (1996)
  • "3rd Conference on Retroviruses and Oppourtunistic Infections" (1996)
  • "Clinical evaluation of cytokine profile switching in HIV+ patients" IDSA 3rd Conference on Retroviruses and Opportunistic Infections (1996)
  • "Concentration-targeted delavirdine therapy in 82 patients in ACTG 260" IDSA 3rd Conference on Retroviruses and Opportunistic Infections (1996)
  • "Delavirdine (DLV) Susceptibility of HIV-1 Isolates Obtained From Patients (pts) Receiving DLV Monotherapy (ACTG 260)" 3rd Conference on Retroviruses and Opportunistic Infections (1996)
  • "Menstrual cycle hormone patterns in HIV-infected women" IDSA 3rd Conference on Retroviruses and Opportunistic Infections (1996)
  • "Randomized phase I/II concentration-controlled trial of the anti-HIV activity of delavirdine" 3rd Conference on Retroviruses and Opportunistic Infections (1996)
  • "Delavirdine dosage requirements during a concentration-targeted study" 35th ICAAC (1995)
  • "Effect of food on the steady-state pharmacokinetics of delavirdine mesylate in HIV-positive patients" 35th ICAAC (1995)
  • "High frequency of Helicobacter pylori co-infection in HIV+ subjects with gastric hypoacidity" 35th ICAAC (1995)
  • "In vitro protein binding of delavirdine and its N-dealkylated metabolite" 35th ICAAC (1995)
  • "Reduced delavirdine exposure in HIV+ subjects with gastric hypoacidity" 35th ICAAC (1995)
  • "Combination therapy with delavirdine and ddl, but not AZT, fails to prevent the emergence of Y181C in nucleoside experienced patients" Fourth International HIV Drug Resistance Workshop (1995)
  • "Delavirdine susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy (ACTG 260)" Fourth International HIV Drug Resistance Workshop (1995)
  • "Advances in HIV Treatment" NYSCCP (1995)
  • "Susceptibility of HIV-1 isolates to delavirdine, a bisheteroarylpiperazine (BHAP) nonnucleoside reverse transcriptase inhibitor in patients receiving DLV in combination with nucleoside RT inhibitors" Eight International Conference on Antiviral Research (1995)
  • "Antiretroviral Therapy" , University of Miami, School of Medicine (1995)
  • "AZT resistant HIV-1 isolates obtained during ddl monotherapy from a patient with no history of AZT use" 2nd National Conference on Human Retroviruses and Related Infections (1995)
  • "Comparison of measured and estimated creatinine clearance in patients with advanced HV disease" 2nd National Conference on Human Retroviruses and Related Infections (1995)
  • "Didanosine population pharmacokinetics relationship between drug exposure and surrogate marker response" 2nd National Conference on Human Retroviruses and Related Infections (1995)
  • "Gastric Hypoacidity among HIV-infected patients" 2nd National Conference on Human Retroviruses and Related Infections (1995)
  • "Zidovudine recovery from phosphorylated and anabolites under different experimental conditions using two types of alkaline phosphatase" 2nd National Conference on Human Retroviruses and Related Infections (1995)
  • "Validation of alkaline phosphatase used to quantify intracellular zidovudine metabolites" Second International Congress on Drug Therapy in HIV Infection (1994)
  • "Didanosine reduces atevirdine absorption" 34th ICAAC (1994)
  • "Effect of didanosine population pharmacokinetics of delavirdine" 34th ICAAC (1994)
  • "Recovery of zidovudine from mono-, di-, and triphosphate salts using two different alkaline phosphatases" 34th ICAAC (1994)
  • "Zidovudine pharmacokinetics during an escalating, multiple-dose study of delavirdine" 34th ICAAC (1994)
  • "Phase II clinical trials of delavirdine mesylate combination therapy" International Conference on AIDS (1994)
  • "A comparison of creatinine clearance estimations to measured creatinine clearance in hospitalized patients with advanced HIV disease" Annual Meeting of the American College of Clinical Pharmacy (1994)
  • "Didanosine population pharmacokinetics among HIV-infected outpatients" 1st National Conference Human Retroviruses and Related Infections (1993)
  • "Phase 1 study of atevirdine (ATV), a non-nucleoside reverse transciptase inhibitor (NNRTI)" 1st Naional Conference Human Retroviruses and Related Infections (1993)
  • "Zalcitabine (ddC) exposure: lack of impact on CD4 and weight response during combination therapy with zidovudine (ZDV) after previous ZDV therapy" 1st National Conference Human Retroviruses and Related Infections (1993)
  • "Antiviral Pharmacokinetics" ICAAC (1993)
  • "Atevirdine and zidovudine blood distribution" 33rd ICAAC (1993)
  • "Comparative blood distribution of zidovudine, ATV and an ATV metabolite" 33rd ICAAC (1993)
  • "Disposition of ATV in ACTG 199" 33rd ICAAC (1993)
  • "Influence of disease progression on ZDV pharmacokinetics in females infected with HIV" 33rd ICAAC (1993)
  • "Intracellular zidovudine metabolism in lymphocytes" 33rd ICAAC (1993)
  • "Zidovudine pharmacodynamics in HIV infected patients" 33rd ICAAC (1993)
  • "Comparative Antiviral Activity, Intracellular Biochemistry, and Clinical Pharmacology of Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors" Annual Meeting of the American College of Clinical Pharmacy, American College of Clinical Pharmacy (1993)
  • "New Developments in Antiretroviral Therapy for HIV" Annual Meeting of the American College of Clinical Pharmacy, American College of Clinical Pharmacy (1993)
  • "Zalcitabine population pharmacokinetics" Annual Meeting of the American College of Clinical Pharmacy (1993)
  • "New Developments in HIV Therapy" , Case Western Reserve University (1993)
  • "Atevirdine (ATV) pharmacokinetics (PK) and dosage requirements during a concentration-targed (CT) phase I study" XI International Conference on AIDS (1993)
  • "Atevirdine disposition and dosage requirements during a concentration targeted phase I trial" X International AIDS Symposium (1993)
  • "Atevirdine pharmacoknetics and dosage requirements during a concentration-targeted phase I study" IX International Conference on AIDS (1993)
  • "Comparative blood distribution of zidovudine, atevirdine, and an ATV metabolite" X International AIDS Symposium (1993)
  • "In vitro intravascular distribution of a highly plasma protein bound nonnucleoside reverse transcriptase inhibitor (NNRTI)" IX International Conference AIDS (1993)
  • "Antiviral Therapy for HIV Infection" Faculty Conference, University of Wisconsin (1993)
  • "Antiviral Therapy for HIV Infection" Spring Clinic, State University of New York at Buffalo, State University of New York at Buffalo (1993)
  • "Colony Stimulating Factors" Biotechnology Symposium, Albany College of Pharmacy (1993)
  • "Erythropoietin Therapy" Biotechnology Symposium, Albany College of Pharmacy (1993)
  • "Human Pharmacokinetics of Atevirdine" Upstate New York Infectious Disease Meeting (1993)
  • "Zidovudine food effect" American Society of Clinical Pharmacology and Therapeutics (1993)
  • "Intracellular/extracellular relationshiop of zidovudine in mononuclear cells isolated from whole blood in vitro" 1st International Congress on Drug Therapy in HIV Infection (1992)
  • "Zidovudine recovered from peripheral blood mononuclear cells of HIV-infected patients" 1st International Congress on Drug Therapy in HIV Infection (1992)
  • "Zidovudine pharmacokinetics in HIV+ women during the menstrual cycle" 32nd ICAAC (1992)
  • "Antiretroviral Therapy for HIV Infection" Medical Grand Rounds, Moses Cone Memorial Hospital (1992)
  • "New Treatments for HIV Infection" Area Health Education Center Program, Wake AHEC (1992)
  • "Pharmacokinetics of zidovudine and didanosine during combinatio therapy in ACTG Protocol 143" VIII Inter AIDS Conference (1992)
  • "Zidovudine pharmacokinetics in HIV-positive women" VIII International AIDS Conference (1992)
  • "U87201E and zidovudine pharmacokinetics in ACTG 199" 14th ACTG Meeting (1992)
  • "Antiviral Therapy for AIDS" , University of Rhode Island (1992)
  • "Antiretroviral Therapy" , Department of Pharmaceutical Services, UCLA Medical Center (1992)
  • "New Anti-infectives and Treatments for HIV Disease" Midwinter Practice and Research Forum, American College of Clinical Pharmacy (1992)
  • "Saliva Concentrations of Zidovudine" Annual Meeting of the American College of Clinical Pharmacy (1992)
  • "Zidovudine distribution into blood components" Second Annual Winter Practice and Research Forum of the ACCP (1992)
  • "Antivirals New Drug Update" State University of New York at Buffalo School of Pharmacy Continuing Education Program, SUNY at Buffalo, School of Pharmacy (1991)
  • "Prolonged elimination of zidovudine detected by radioimmunoassay in HIV-positive hemophilia patients" 13th ACTG Meeting (1991)
  • "Zidovudine assay correlation RIA vs. HPLC" 13th ACTG Meeting (1991)
  • "Antiviral Neurotoxicity" WNY Fall Conference on AIDS (1991)
  • "Beyond nucleoside analogs" Infectious Disease Symposium, St. John's University (1991)
  • "Pharmacokinetics of granulocyte-macrophage colony stimulating factor in AIDS/ARC patients" VII International AIDS Conference (1991)
  • "Treatment of HIV Infection" Pharm.D. Therapeutics Lecture, University of Wisconsin (1991)
  • "Zidovudine and GMCSF" Research Conference, Mary Imogene Bassett Hospital (1991)
  • "Colony stimulating factors potential role as treatment for infectious diseases in dialysis patients" , Medical College of Virginia (1991)
  • "Colony stimulating factors potential role as treatment for infectious diseases in dialysis patients" Nephrology Conference, Georgetown University (1991)
  • "Correlation of Peritoneal Solute Clearance with Altered Cefonicid Protein Binding" Dept of Medicine, Spring Clinical Day, SUNY at Buffalo (1991)
  • "Prolonged Elimination of Zidovudine in Hemophilia Patients with HIV infected detected by radioimmunoassay" Dept of Medicine, Spring Clinical Day, SUNY at Buffalo (1991)
  • "Prolonged elimination of zidovudine detected by radioimmunoassay" 11th ACTG Meeting (1991)
  • "Antivirals new drug update" State University of New York at Buffalo School of Pharmacy Continuing Education Program, SUNY at Buffalo, School of Pharmacy (1991)
  • "Current treatment of HIV infection" Nevada Pharmaceutical Association Meeting (1990)
  • "Therapeutic drug monitoring of antivirals" Midyear Clinical Meeting of the American Society of Hospital Pharmacists, American Society of Hospital Pharmacists (1990)
  • "Influence of GMCSF on zidovudine pharmacokinetics" Upstate Infectious Disease Pharmacy Practitioners Meeting (1990)
  • "Immunotherapy for HIV Infection" Treatment of AIDS and its Complications in the 1990's Conference (1990)
  • "New applications for colony stimulating factors" Cinical Pharmacy Grand Rounds, Montefiore Medical Center (1990)
  • "Zidovudine pharmacokinetics" Pharmacy Research Conference, St. John's University (1990)
  • "Cefonicid disposition in geriatric patients with baterial pneumonia" XI Annual Meeting of the ACCP (1990)
  • "Comparative oral disposition of zidovudine in neutropenic AIDS patients and asymptomatic HIV-infected hemophiliacs" Annual Meeting of the ACCP (1990)
  • "Reliability of single-dose intraperitoneal vancomycin therapy for gram-positive peritonitis" XI Annual Meeting of the ACCP (1990)
  • "Variability of digoxin-like immunoreactive substance among hermodialysis patients" XI Annual Meeting of the ACCP (1990)
  • "Comparative Oral Disposition of Zidovudine in Neutropenic AIDS patients and asymptomatic hemophiliacs" Pharmaceutics Symposium (1990)
  • "Comparative oral disposition of zidovudine in neutropenic AIDS patient and asymptomatic hemophiliacs" VI International Conference AIDS (1990)
  • "Concurrent administration of granulocyte-macrophage colony-simulating factor and zidovudine in patients with AIDS/ARC" VI International AIDS Conference (1990)
  • "Zidovudine (ZDV) pharmacokinetics in AIDS patients receiving granulocyte-monocyte colony stimulating factor (GMCSF)" Sixth International Conference on AIDS (1990)
  • "Zikovudine pharmacokinetics in AIDS patients receiving granulocyte macrophage colony stimulating factor" VI International AIDS Conference (1990)
  • "New developments in the management of the acquired immune deficiency syndrome" SUNY at Buffalo School of Pharmacy Alumni Spring Clinic, SUNY at Buffalo, School of Pharmacy (1990)
  • "Pharmacology of anti-HIV nucleosides" Infectious Disease Grand Rounds, SUNY Upstate Medical Center (1990)
  • "Pharmacology of HIV Infection" Update on AIDS and HIV Infection, Health Care Providers in New York State Correctional Facilities (1990)
  • "Role of the pharmacist in the AIDS epidemic" Wayne State University, Wayne State University (1990)
  • "Renal excretion pattern of zidovudine and zidovudine glucuronide during multiple dosing" Ninety-First Meeting ASCPT (1990)
  • "Zidovudine and dideoxyinosine pharmacology in AIDS patients" SUNYAB Infectious Disease Research Seminar (1990)
  • "Current status of AIDS treatment" Western New York Society of Hospital Pharmacists, Western New York Society of Hospital Pharmacists (1989)
  • "Dideoxyinosine pharmacokinetics in patients with AIDS and ARC" 7th ACTG Meeting (1989)
  • "Renal excretion pattern of zidovudine and zidovudine glucuronide during multiple dosing" 7th ACTG Meeting (1989)
  • "Treatment of peritonitis in CAPD patients" SUNYAB Renal Seminar (1989)
  • "Dideoxyinosine administration to patients with AIDS and ARC" 29th ICAAC (1989)
  • "Zidovudine pharmacokinetics in AIDS patients" Bristol-Myers Laboratories, Bristol-Myers Laboratories (1989)
  • "Zidovudine pharmacokinetics" Upstate New York Infectious Disease Pharmacy Meeting (1989)
  • "Pharmacokinetics of intravenous oral zidovudine in hemophiliac patients with human immunodeficiency virus infection" V International AIDS Symposium (1989)
  • "Phase I study of dideoxyinosine in AIDS patients" V International AIDS Symposium (1989)
  • "Drug dosing in renal failure patients" Third Annual Board Review Course in Medicine, State University of New York at Buffalo, School of Medicine (1989)
  • "Dideoxyinosine pharmacokinetics in patients with AIDS and ARC" 4th ACTG Meeting (1989)
  • "Infections in the dialysis patient" Atlanta Pharmacy Symposium, University of Georgia, College of Pharmacy (1989)
  • "Infections in the dialysis patient" New Orleans Pharmacy Symposium, Xavier University of Lousiana at New Orleans (1989)
  • "Buffalo Infectious Disease Therapeutics Symposium" Buffalo Infectious Disease Therapeutics Symposium (1989)
  • "Crital care therapeutics" Mini-Course, Department of Pharmaceutical Services, Erie County Medical Center (1989)
  • "Recent developments in the treatment of HIV disease" Western New York Society of Hospital Pharmacists, Western New York Society of Hospital Pharmacists (1989)
  • "Multiple dose ZDV kinetics in hemophilia patients with liver dysfunction and HIV infection" 28th ICAAC (1988)
  • "Pharmacokinetics and coagulation studies of azidothymidine in hemophiliac patients asymptomatically infected with the human immunodeficiency virus" IV International AIDS Symposium (1988)
  • "Single dose oral pharmacokinetics of zidovudine in patients with hemophilia" 3rd ACTG Meeting (1988)
  • "Cyclosporine Metabolism in the acute post-operative period" New York State Transplantation Conference (1988)
  • "Special considerations for antobiotic dosing in geriatric patients" Management of Infectious Diseases in the Elderly Meeting, SUNY at Buffalo School of Medicine (1988)
  • "Antibiotic Nephrotoxicity" Western New York Urologic Nurses Association, Western New York Urologic Nurses Association (1988)
  • "Diuretic hypokalemia pathophysiology and management" Philadelphia County Medical Society, Philadelphia County Medical Society (1987)
  • "Protein binding of a high-affinity cephalosporin during CAPD" American Society of Nephrology (1987)
  • "Antibiotic pharmacokinetics during continuous ambulatory peritoneal dialysis" University of North Carolina, School of Pharmacy, University of North Carolina, School of Pharmacy (1987)
  • "Antibiotic therapy in patients with renal disease" Clinical Practice SIG Annual Meeting, North Carolina Society of Hospital Pharmacists (1987)
  • "Intraperitoneal antibiotic pharmacokinetics and the treatment of peritonitis" Nephrology Division, University of Georgetown Medical School (1987)
  • "Vancomycin degradation products which cross-react with fluorescence polarization immunoassay during peritoneal dialysis" ASCPT (1987)
  • "Influence of altered protein binding on bactericidal activity during CAPD" Meeting of the American Society of Nephrology (1986)
  • "Vancomycin pharmacokinetics in patients with and without peritonitis" Meeting of the American Society of Nephrology (1986)
  • "Influence of peritonitis on absorption of intraperitoneal vancomycin" 26th ICAAC (1986)
  • "Effects of Hilicobacter pylori treatment on gastric pH and delavirdine mesylate pharmacokinetics in HIV+ patients with gastric hypoacidity" 36th ICAAC (1986)
  • "Influence of Peritonitis on Absorption of Intraperitoneal Vancomycin" New York State Infectious Disease Conference (1986)
  • "Cyclosporine pharmacokinetics" SUNYAB Transplantation Program, Buffalo General Hospital (1986)
  • "Implications of Drug-Protein Binding in CAPD patients" Department of Medicine Research Day (1986)
  • "Therapeutics update on hypertension" SUNYAB School of Pharmacy Continuing Education Program (1986)
  • "Antibiotic Pharmacokinetics during CAPD" Pharmaceutics Symposium (1985)
  • "Individualization of tobramycin dosing in CAPD patients" ACCP (1985)
  • "Cefamandole pharmacokinetics in CAPD patients with and without pertonitis" ASCPT (1985)
  • "Clinical Pharmacokinetic Characteristics of the Peritoneum" Clinical Pharmacy Conference, National Institutes of Health (1984)
  • "Intraperitoneal moxalactam during CAPD" III International Symposium on CAPD (1984)
  • "Moxalactam epimer kinetics during CAPD" ACCP (1984)
  • "Hypertension update - Newer concepts in pathophysiology and drug therapy" , Pharmaceutical Society of the State of New York (1984)
  • "Drug-induced sexual dysfunction" , Western New York Society of Hospital Pharmacists (1983)
  • "Beta-blockade after myocardial infarction" , SUNYAB Pharmacy School Women's Alumni (1982)
  • "Pharmacist role in resistant hypertension" ASHP (1981)
See all (382 more)
Service Activities:
  • ACTG Protocol A5368; NIH NIAID ACTG Protocol A5368 Protocol Pharmacologist; Other (2017–present)
  • ACTG Protocol 5366; NIH NIAID ACTG Protocol 5366 Protocol Pharmacologist; Other (2016–present)
  • ACTG Protocol A5360; NIH NIAID ACTG Protocol A5360 Protocol Pharmacologist; Other (2016–present)
  • "Emerging Epidemic Virus Research Training" meeting, NIH D71 Review Committee.; Chair (2016)
  • ACTG Protocol 5358; NIH NIAID ACTG Protocol 5358 Protocol Pharmacologist; Other (2016–present)
  • NCCIH, Basic Research on HIV Persistence (R01); Reviewer (2015–present)
  • NCCIH, Herb-Drug Interactions Centers Review Panel (U54); Reviewer (2015–present)
  • NIAID - ACTG, Hepatitis Transformative Science Group Study Monitoring Committee; Member (2014–present)
  • ACTG Protocol 5339; NIH NIAID ACTG Protocol 5339 Protocol Pharmacologist; Other (2014–2015)
  • NIMH, Novel NeuroAIDS Therapeutics: Integrated Preclinical/Clinical Program (P01); Reviewer (2014–present)
  • NIH, Fogarty Global Infectious Disease Research Training Program (D43); Reviewer (2013–present)
  • ACTG Protocol 5334s; NIH NIAID ACTG Protocol 5334s Protocol Pharmacologist; Other (2013–present)
  • ACTG Protocol 5335s; NIH NIAID ACTG Protocol 5335s Protocol Pharmacologist; Other (2013–present)
  • NIAID Investigator Initiated Program Project Applications (P01); NIAID; Other (2013)
  • AIDS/Related Research Integrated Review Group; AIDS/Related Research Integrated Review Group; Other (2013)
  • Prevention of HIV Transmission and Acquisition Through a Better Understanding of Reproductive Health (R01/R03); NIAID/NICHD; Other (2013)
  • AIDS Clinical Trials Group Protocol 5329; NIH/NIAD ACTG Protocol 5329; Other (2013)
  • Site Visit Assessment at John's Hopkins University Pharmacology Laboratory; NIH/NIAID Clinical Pharmacology Quality Assurance Program; Other (2013)
  • AIDS Clinical Trials Group Protocol 5328; NIH/NIAD ACTG Protocol 5238; Other (2013)
  • UB Patient Centered Outcomes Research Institute (PCORI); Reviewer (2013–present)
  • TL1 Steering Committee; Other (2012)
  • Tenure and Promotion Committee; Co-Chair (2012)
  • ACTG Neurology Collaborative Science Group; NIH NIAID ACTG Neurology Collaborative Science Group; Other (2012)
  • Centers for AIDS Research (CFAR); NIAID; Other (2011)
  • ACTG Clinical Pharm. Advisory Group, Laboratory Steering Committee; NIH NIAID; Other (2011)
  • HIV Reservoirs Sampling Focus Group; NIH NIAID ACTG HIV Reservoirs Sampling Focus Group; Other (2011)
  • Pharmacogenomics and HIV Therapy; NIH NIAID Pharmacogenomics and HIV Therapy; Other (2011)
  • ACTG Chimerix/CMX-157 Working Group; NIH NIAID - ACTG Chimerix-CMX-157; Other (2011)
  • ACTG Hepatitis Transformative Science Group; NIH NIAID ACTG Hepatitis Transformative Science Group; Other (2011)
  • ACTG Protocol 5296; NIH NIAID ACTG Protocol 5296 Protocol Pharmacologist; Other (2011)
  • AIDS Clinical Trials Group Protocol 5309; NIH/NIAID ACTG protocol 5309; Other (2011)
  • NIH, Center for Scientific Review; ACTG International Pharmacology Specialty Laboratories (IPSL); Other (2011)
  • ACTG Protocol 5294; NIH NIAID ACTG Protocol 5294 Protocol Pharmacologist; Other (2010)
  • NIH, Center for Scientific Review; NIAID Clinical Trial Planning & Implementation Grants; Other (2010)
  • ACTG Protocol 5292; NIH NIAID ACTG Protocol 5292 Protocol Pharmacologist; Other (2010)
  • NIH, Center for Scientific Review; Center for AIDS Research Applications; Other (2010)
  • NIH, Center for Scientific Review; NINDS, NSDK Review; Other (2010)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Director, ACTG Pharmacology Specialty Laboratory Core; Other (2010)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG Executive Committee; Other (2010)
  • UB Clinical and Translational Science Award (CTSA) Program; Program designed to facilitate clinical and translational research by applying for large infrastructure grants that integrate various institutions. Current collaborating institutions include Roswell Park and the Hauptman-Woodward Institute.; Member (2009)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, OHARA Oral PK Focus Group; Other (2009)
  • Center for Human Experimental Therapeutics (CHET), UR CTSA; Member (2009)
  • NIH, Center for Scientific Review; Special Emphasis Panel, R31/U01 Review; Other (2009)
  • NIH, Center for Scientific Review; AIDS Clinical Trials Review Panel; Other (2009)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5277; Other (2009)
  • Upstate New York Translational Research Network (UNYTR), UR CTSA; Member (2009)
  • UB Clinical and Translational Research Center (CTRC) Planning Committee; Stimulate clinical and translational research at UB which will lead to both new and innovative research findings as well as funding. This initiative will help drive UB into a leading research institute.; Member (2009)
  • NIH, NIAID - Protocol Pharmacologist, ACTG Protocol 5202; Other (2008)
  • NIH, NIAID - Protocol Pharmacologist, ACTG Protocol 5261; Other (2008)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5175; Other (2008)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5235; Other (2008)
  • NIH, Center for Scientific Review; Special Emphasis Panel, Shacker P01 Review; Other (2008)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Chair, Hepatic Function Working Group; Other (2007)
  • Residency Advisory Committee; Residency Advisory Committee; Other (2007)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG Hepatitis Research Committee; Other (2007)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG Phase I/II ART Focus Group; Other (2007)
  • SPPS/PRC Office of International Education and Research; SPPS/PRC Office of International Education and Research; Other (2007)
  • Freshman Discovery Seminar, Translational Pharmacogenomics; Coordinator (2007)
  • NIH, Center for Scientific Review; Member, NIAID, HIV Resevoirs; Other (2007)
  • NIH, Center for Scientific Review; Member, Special Emphasis Panel - HIV/AIDS Project Application; Other (2007)
  • NIH, Center for Scientific Review; NIAID Clinical Trial Planning (R34) Grants; Other (2007)
  • Board of Directors; PARI Support Group (Harare, Zimbabwe); Other (2007)
  • International AIDS Society-USA Core Faculty; International AIDS Society-USA Core Faculty; Other (2007)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, R5 Tropic Protocol Committee; Other (2006)
  • PHM 510 - Fluid and Electrolytes; Coordinator (2006)
  • Department of Pharmacy Practice Seminar Series; Other (2006)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5236; Other (2006)
  • Translational Pharmacology Research Core (TPRC); Other (2006)
  • NIH, Center for Scientific Review; AIDS Clinical Studies and Epidemiology Study; Other (2005)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG Experimental Research Agenda Committee; Other (2005)
  • Self-Study Accreditation Committee; Self-Study Accreditation Committee; Other (2005)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Chair, ACTG Pharmacology Lab Subcommittee; Other (2004)
  • NIH, Center for Scientific Review; AIDS/Related Research Integrated Review Group; Other (2004)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Investigator, ACTG 5213; Other (2004)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Vice-Chair, ACTG Pharmacology Lab Subcommittee; Other (2003)
  • NIH, Center for Scientific Review; NIAID, Pediatric AIDS Clinical Trials Group; Other (2003)
  • Co-Director; International Center for HIV/AIDS Pharmacotherapy Research and Training (ICHAPRT); Other (2002)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG Pharmacology Leadership Subcommittee; Other (2002)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5135; Other (2001)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5146; Other (2001)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 5149; Other (2001)
  • NIH, Center for Scientific Review; NIMH, Member, Special Emphasis Panel; Other (2001)
  • NIH, Center for Scientific Review; Pediatric AIDS Clinical Trials Group Review Group; Other (2001)
  • Portfolio 403, 502; Coordinator (2000)
  • NIH, Center for Scientific Review; AIDS/Related Research Integrated Review Group; Other (2000)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Chair, ACTG Pharmacology QA-QC Subcommittee; Other (2000)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Chair, Adult ACTG Pharmacology Committee; Other (2000)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Chair, ACTG Protocol 5043; Other (1999)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 388; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 384; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 368; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 370; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 372; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 868; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Vice Chair, ACTG Adult Pharmacology Committee; Other (1997)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG HIV Research Agenda Committee; Other (1997)
  • Executive Committee; Executive Committee; Other (1996)
  • Department of Pharmacy Practice; Other (1996)
  • PHM 491, 492, 493 - Disease and Therapeutics; Coordinator (1995)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 260; Other (1993)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 261; Other (1993)
  • Faculty Senate; Faculty Senate; Other (1992)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 187; Other (1991)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 199; Other (1991)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG, NIAID, Opportunistic Infectious Committee; Other (1991)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 135; Other (1991)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Protocol Pharmacologist, ACTG Protocol 143; Other (1991)
  • NIH,NIAID, Protocol Pharmacologist, ACTG Protocol 156; Other (1991)
  • Faculty Senate; Faculty Senate; Other (1990)
  • SPPS Subcommittee: Evaluation, Experimentation and Innovation; SPPS Subcommittee: Evaluation, Experimentation and Innovation; Other (1990)
  • Faculty Recruitment; Center for Clinical Pharmacy Research; Other (1990)
  • Promotions Committee; Center for Clinical Pharmacy Research; Other (1990)
  • Center for Clinical Pharmacy Research; Center for Clinical Pharmacy Research; Other (1989)
  • Department of Pharmacy Seminar; Other (1989)
  • PHM 491, 492, 493 - Disease and Therapeutics; Coordinator (1989)
  • Department of Pharmacy; Member (1988)
  • NIH, National Institute for Allergy and Infectious Diseases (NIAID); Member, ACTG, NIAID, Pharmacology Committee; Other (1988)
  • Department of Pharmacy; Member (1986)
  • Curriculm Committee; Doctor of Pharmacy Program; Other (1986)
  • Curriculm Committee; Doctor of Pharmacy Program; Other (1984)
  • PHM 510 - Advanced Pharmacotherapeutics I; Coordinator (1984)
  • PHM 511 - Advanced Pharmacotherapeutics II; Coordinator (1984)
  • PHM 511 - Nutrician; Coordinator (1984)
  • PHM 512 - Advanced Pharmacotherapeutics III; Coordinator (1984)
  • PHM 512 - Gastroenterology; Coordinator (1984)
  • Policy and Implementation Committee, Pharm.D.; Policy and Implementation Committee, Pharm.D.; Other (1984)
  • PHM 510 - Fluid and Electrolytes; Coordinator (1983)
  • UB, Doctor of Pharmacy Students; Member (1983)

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

NYS Center of Excellence in Bioinformatics and Life Sciences
Translational Pharmacology Research Core
701 Ellicott Street
Buffalo, NY 14203
Phone: (716) 881-7464
Fax: N/A
Email: emorse@buffalo.edu


Log in to Update Your Profile
"); pageTracker._trackPageview();